Protumoral lipid droplet-loaded macrophages are enriched in human glioblastoma and can be therapeutically targeted.


Journal

Science translational medicine
ISSN: 1946-6242
Titre abrégé: Sci Transl Med
Pays: United States
ID NLM: 101505086

Informations de publication

Date de publication:
30 Oct 2024
Historique:
medline: 31 10 2024
pubmed: 30 10 2024
entrez: 30 10 2024
Statut: ppublish

Résumé

Glioblastoma presents a formidable clinical challenge because of its complex microenvironment. Here, we characterized tumor-associated foam cells (TAFs), a type of lipid droplet-loaded macrophage, in human glioblastoma. Through extensive analyses of patient tumors, together with in vitro and in vivo investigations, we found that TAFs exhibit distinct protumorigenic characteristics related to hypoxia, mesenchymal transition, angiogenesis, and impaired phagocytosis, and their presence correlates with worse outcomes for patients with glioma. We further demonstrated that TAF formation is facilitated by lipid scavenging from extracellular vesicles released by glioblastoma cells. We found that targeting key enzymes involved in lipid droplet formation, such as diacylglycerol

Identifiants

pubmed: 39475570
doi: 10.1126/scitranslmed.adk1168
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

eadk1168

Auteurs

Valeria Governa (V)

Division of Oncology, Department of Clinical Sciences, Lund, Lund University, Lund 221 00, Sweden.

Kelin Gonçalves de Oliveira (KG)

Division of Oncology, Department of Clinical Sciences, Lund, Lund University, Lund 221 00, Sweden.

Anna Bång-Rudenstam (A)

Division of Oncology, Department of Clinical Sciences, Lund, Lund University, Lund 221 00, Sweden.

Svenja Offer (S)

Joint Mass Spectrometry Center (JMSC) at Comprehensive Molecular Analytics, Helmholtz Zentrum München, Neuherberg 85764, Germany.

Myriam Cerezo-Magaña (M)

Division of Oncology, Department of Clinical Sciences, Lund, Lund University, Lund 221 00, Sweden.

Jiaxin Li (J)

Division of Oncology, Department of Clinical Sciences, Lund, Lund University, Lund 221 00, Sweden.

Sarah Beyer (S)

Division of Oncology, Department of Clinical Sciences, Lund, Lund University, Lund 221 00, Sweden.

Maria C Johansson (MC)

Division of Oncology, Department of Clinical Sciences, Lund, Lund University, Lund 221 00, Sweden.

Ann-Sofie Månsson (AS)

Division of Oncology, Department of Clinical Sciences, Lund, Lund University, Lund 221 00, Sweden.

Charlotte Edvardsson (C)

Division of Oncology, Department of Clinical Sciences, Lund, Lund University, Lund 221 00, Sweden.

Faris Durmo (F)

Division of Diagnostic Radiology, Department of Clinical Sciences, Lund, Lund University, Lund 221 00, Sweden.

Emma Gustafsson (E)

Division of Oncology, Department of Clinical Sciences, Lund, Lund University, Lund 221 00, Sweden.

Axel Boukredine (A)

Division of Oncology, Department of Clinical Sciences, Lund, Lund University, Lund 221 00, Sweden.

Pauline Jeannot (P)

Division of Translational Cancer Research, Department of Laboratory Medicine, Lund, Lund University, Lund 221 00, Sweden.

Katja Schmidt (K)

Infectious Diseases and Immunodeficiency Section, Department of Medicine 3, University Hospital Erlangen, Friedrich-Alexander-University Erlangen, Erlangen 91054, Germany.

Emelie Gezelius (E)

Division of Oncology, Department of Clinical Sciences, Lund, Lund University, Lund 221 00, Sweden.

Julien A Menard (JA)

Division of Oncology, Department of Clinical Sciences, Lund, Lund University, Lund 221 00, Sweden.

Raquel Garza (R)

Laboratory of Molecular Neurogenetics, Department of Experimental Medical Science, Wallenberg Neuroscience Center and Lund Stem Cell Center, Lund University, Lund 221 00, Sweden.

Johan Jakobsson (J)

Laboratory of Molecular Neurogenetics, Department of Experimental Medical Science, Wallenberg Neuroscience Center and Lund Stem Cell Center, Lund University, Lund 221 00, Sweden.

Therese de Neergaard (T)

Division of Infection Medicine, Department of Clinical Sciences, Lund, Lund University, Lund 221 00, Sweden.

Pia C Sundgren (PC)

Division of Diagnostic Radiology, Department of Clinical Sciences, Lund, Lund University, Lund 221 00, Sweden.
Lund Bioimaging Centre, Lund University, Lund 221 00, Sweden.
Department of Medical Imaging and Function, Skåne University Hospital, Lund 221 85, Sweden.

Aliisa M Tiihonen (AM)

Prostate Cancer Research Center, Faculty of Medicine and Health Technology, Tampere University and Tays Cancer Center, Tampere University Hospital, Tampere 33101, Finland.

Hannu Haapasalo (H)

Fimlab Laboratories Ltd., Tampere University Hospital, Tampere 33101, Finland.

Kirsi J Rautajoki (KJ)

Prostate Cancer Research Center, Faculty of Medicine and Health Technology, Tampere University and Tays Cancer Center, Tampere University Hospital, Tampere 33101, Finland.

Pontus Nordenfelt (P)

Division of Infection Medicine, Department of Clinical Sciences, Lund, Lund University, Lund 221 00, Sweden.

Anna Darabi (A)

Division of Neurosurgery, Department of Clinical Sciences, Lund, Lund University, Lund 221 00, Sweden.

Karin Forsberg-Nilsson (K)

Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala 751 85, Sweden.
Biodiscovery Institute, University of Nottingham, Nottingham NG7 2QL, UK.
Science for Life Laboratory, Uppsala 752 37, Sweden.

Alexander Pietras (A)

Division of Translational Cancer Research, Department of Laboratory Medicine, Lund, Lund University, Lund 221 00, Sweden.

Hugo Talbot (H)

Division of Oncology, Department of Clinical Sciences, Lund, Lund University, Lund 221 00, Sweden.

Johan Bengzon (J)

Division of Neurosurgery, Department of Clinical Sciences, Lund, Lund University Hospital, Lund 221 85, Sweden.

Mattias Belting (M)

Division of Oncology, Department of Clinical Sciences, Lund, Lund University, Lund 221 00, Sweden.
Department of Hematology, Oncology and Radiophysics, Skåne University Hospital, Lund 221 85, Sweden.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH